AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03514602 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multicomponent behavioral intervention
Description: Pregnant patients in the intervention group will receive multicomponent interventions consisting of education, feedback, contingent financial incentives, and peer support. At initial intervention visit, they will choose a quit date within the next 14 days and sign a no-smoking pledge and a no-smoking contract. The contract lists the intervention components, the patient's and the counselor's responsibilities, importance of keeping scheduled visits, and rules on contingent incentives. After the quit date, pregnant women will meet with counselors daily for 5 consecutive days (Monday to Friday) for abstinence monitoring in weeks 1-2. The frequency of abstinence monitoring will decrease to twice a week (Monday and Thursday) in weeks 3-8, weekly in weeks 9-12, and biweekly in weeks 13 until delivery.
Study NCT03514602 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Education only control
Description: The control group will receive one 60-minute counseling mainly based on a pregnancy-tailored self-help booklet entitled Need Help Putting Out That Cigarette? distributed by the American College of Obstetricians and Gynecologists.
Study NCT01260506 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VB-111
Study NCT01260506 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Upon progression, subjects will receive a combination therapy of VB-111 and standard of care bevacizumab
Study NCT03104803 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: long-term paired associative stimulation
Description: Paired associative stimulation (PAS) administered several times per week for 6 weeks to one hand. PAS comprises transcranial magnetic stimulation (eXimia magnetic stimulator, Nexstim Ltd, Helsinki, Finland) and peripheral nerve stimulation (given with Dantec Keypoint® electroneuromyography device (Natus Medical Incorporated, Pleasanton, CA, USA)).
Study NCT03318068 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Yoga Intervention
Description: The yoga intervention will consist of a combination of yoga postures, gentle stretches, breathing techniques and relaxation. The sessions will be delivered one-on-one and will be adapted to accommodate the patients each day.
Study NCT03003689 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Scaling and Root Planing
Description: Standard of care scaling and root planing using hand instruments and ultrasonic scaler
Study NCT03003689 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Scaling and Root Planing
Description: Standard of care scaling and root planing using hand instruments and ultrasonic scaler
Study NCT03003689 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Er:YAG Laser
Description: Er:YAG laser as an adjunct therapy to standard of care scaling and root planing using hand instruments and ultrasonic
Study NCT02753673 — intervention group
Intervention type: BEHAVIORAL
Intervention: qualitative interviews with patients
Study NCT02753673 — intervention group
Intervention type: BEHAVIORAL
Intervention: questionnaires
Study NCT03783806 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Posturography measurements
Description: Determination of functional status, Posturography measurements, postural tests
Study NCT03907436 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: USDA Diet
Description: Participants will receive counseling and education on USDA Guidelines for Americans, 2010
Study NCT03907436 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mediterranean Diet
Description: Participants will receive counseling and education on a Mediterranean diet.
Study NCT01334775 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Open anterior inguinal hernia repair
Description: Placement of a surgical mesh in open anterior inguinal hernia repair.
Study NCT01334775 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Open anterior inguinal hernia repair
Description: Placement of a surgical mesh in open anterior inguinal hernia repair.
Study NCT06356493 — intervention group
Intervention type: PROCEDURE
Intervention: caesarean hysterectomy with prior placement of prophylactic occlusion balloons of both internal iliac arteries
Description: Preoperative placement of prophylactic occlusion balloons of both internal iliac arteries (OBIIA) was performed at radiology department. Access to the internal iliac arteries was achieved by retrograde transcutaneous introduction of hydrophilic sheath kits of 8.5 mm under fluoroscopic guidance from both femoral arteries. Once in the lumens of the two internal iliac arteries, the radiologist inflated the balloons until blood flow ceased. The pressure at which occlusion of both internal iliac arteries was achieved was recorded for subsequent replication in the operating room. The radiologist secured the two kits to the skin and applied a compressive dressing. The patient was then directly transferred to the operating room.
Study NCT06356493 — intervention group
Intervention type: PROCEDURE
Intervention: caesarean hysterectomy without prior placement of prophylactic occlusion balloons of both internal iliac arteries
Description: Caesarean hysterectomy was performed through a midline infraumbilical incision. The bladder-uterine peritoneum was dissected, followed by a vertical fundal hysterotomy away from the placenta, and the baby was delivered This was followed by clamping the umbilical cord and closure of the hysterotomy while leaving the placenta in situ without any attempt at traction or delivery and without oxytocin administration.~We proceeded with the remaining steps of hysterectomy.
Study NCT02242630 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylprednisolone, 20 mg
Description: Compared with intrabursal triamcinolone
Study NCT02242630 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylprednisolone, 40 mg
Description: Compared with intrabursal triamcinolone
Study NCT02242630 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triamcinolone, 20 mg
Description: Compared with methylprednisolone
Study NCT02242630 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triamcinolone, 40 mg
Description: Compared with methylprednisolone
Study NCT02869035 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Escitalopram
Description: Patients will be treated with an antidepressant drug (escitalopram) at flexible standard doses for 12 weeks. If no response after 4 weeks; shift to duloxetine arm.
Study NCT02869035 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duloxetine
Description: Patients who at 4 weeks of escitalopram have not responded will be shifted to duloxetine at flexible standard dosages.
Study NCT03639415 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Increasing the Controlled-Release Oxycodone dose frequency
Description: Keep the daily dose while increase the dose frequency of Controlled-Release Oxycodone so that reduce the single dose
Study NCT01188447 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Canadian C-Spine Rule
Description: Paramedics will apply a validated decision rule (the Canadian C-spine Rule) to determine whether or not immobilization is required for trauma patients being transported to the emergency department.
Study NCT00724893 — intervention group
Intervention type: BIOLOGICAL
Intervention: PegIFN-2b
Description: PegIFN-2b powder for solution adminstered subcutaneously using the newly approved Redipen. Dosing per approved labeling
Study NCT00724893 — intervention group
Intervention type: DRUG
Intervention: Ribavirin
Description: Ribavirin capsules administered orally. Dosing in accordance with approved labelling.
Study NCT00592111 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: COPP/ABV
Description: 4 courses of COPP/ABV hybrid
Study NCT00592111 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: COPP/ABV
Description: 6 courses of COPP/ABV hybrid
Study NCT00592111 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intensive chemo with concurrent growth factor
Description: 6 cycles (2 courses) of intensive chemotherapy with concurrent growth factor
Study NCT02657941 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational group
Description: Three weekly sessions of one hour, co-managed by two nurses specialized in psycho-education~Session 1: General information on the risk of weight gain and the means of prevention, motivational balance on the practice of physical activity, developing a personal goal, information about the sports center Session 2: brainstorming and card game on Food Hygiene Session 3: Find situations at risk of snacking and consider alternative lines
Study NCT02657941 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: educational group
Description: Three weekly sessions of one hour, co-managed by two nurses specialized in psycho-education~Session 1: General information on the risk of weight gain and means of prevention, video on physical activity, discussions with therapists, information about the sports center Session 2: Video on Food Hygiene, discussions with therapists Session 3: Return on basic concepts covered in the first 2 sessions
Study NCT02313714 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: stimulation wave (2.5 kHz, burst at 50Hz, on/off: 3/9 sec),
Description: All patients in the treatment arm will receive electric muscular stimulation with a Russian current protocol twice a week for 7 weeks.
Study NCT02313714 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Sham
Description: very low electric muscular stimulation
Study NCT03386227 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Withholding antibiotic prophylaxis
Description: Our intervention will be a deviation from our current standard of care which is universal antibiotic prophylaxis, even in low risk populations. Our intervention will be withholding antibiotic prophylaxis in low risk populations.
Study NCT00559000 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: KIDNET
Description: Narrative Exposure Therapy for Children
Study NCT03188185 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALKS 5461
Description: Samidorphan + buprenorphine, administered sublingually
Study NCT03188185 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ALKS 5461 Placebo
Description: Placebo tablet, administered sublingually
Study NCT03144999 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AAVCAGsCD59
Description: AAVCAGsCD59 is administered as a single intravitreal injection in an office setting
Study NCT00581204 — intervention group
Intervention type: DEVICE
Intervention: Near-Infrared Diffuse Optical Spectroscopy
Description: Early predictor of hemorrhagic shock
Study NCT04028505 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Terlipressin Injectable Product
Description: Intravenous terlipressin will be obtained from Clinical Trials Unit, AKUH pharmacy in standard IV infusion form.~Participants who are randomized to the intervention arm will be administered a continuous infusion of Terlipressin at a rate of 0.5mg/hour for the first 24 hours. Participants randomized into the control group will be administered a bolus form of Terlipressin at a rate of 2mg every six hourly for the first 24 hours respectively. In case of weekends/public holidays intravenous terlipressin will be obtained from the main pharmacy of AKUH.
Study NCT04028505 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Terlipressin Injectable Product
Description: Intravenous terlipressin will be obtained from Clinical Trials Unit, AKUH pharmacy in standard IV infusion form.~Participants who are randomized to the intervention arm will be administered a continuous infusion of Terlipressin at a rate of 0.5mg/hour for the first 24 hours. Participants randomized into the control group will be administered a bolus form of Terlipressin at a rate of 2mg every six hourly for the first 24 hours respectively. In case of weekends/public holidays intravenous terlipressin will be obtained from the main pharmacy of AKUH.
Study NCT00859118 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AG-013736
Description: Axitinib 5 mg PO BID x \~2 weeks (12-14 days), followed by 1 week drug break (for cycle 1 only)
Study NCT00859118 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AG-013736
Description: Axitinib 5 mg PO BID x \~2 weeks (12-14 days), followed by 1 week drug break (for cycle 1 only). After Scan#3 obtained, patients will commence with Axitinib 5 mg PO BID continuously without breaks, repeated in 3 week cycles.
Study NCT00661440 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Neramexane mesylate
Description: 2 double-blind, cross-over treatment periods of 7 weeks separated by a wash-out phase, up to 75 mg Neramexane mesylate per day
Study NCT02622685 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWP10292
Description: Drug: DWP10292 tablets, oral administration, multiple administration
Study NCT02622685 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: DWP10292 Placebo
Description: Placebo tablets, oral administration, multiple administrations
Study NCT02622685 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid (UDCA)
Description: Drug: Ursodeoxycholic acid (UDCA) tablets, oral administration, multiple administration
Study NCT02622685 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: UDCA Placebo
Description: Placebo tablets, oral administration, multiple administrations
Study NCT04767750 — intervention group
Intervention type: OTHER
Intervention: Blood sample collection
Description: 5ml of peripheral blood samples will be collected into tubes containing EDTA from all subjects and the following procedures will be performed:~* Peripheral blood mononuclear cells (PBMCs) will be isolated from blood samples.~* Total RNA extraction from PBMCs by Trizol reagent and spin column.~* Reverse transcription to cDNA.~* The expression levels of lncRNA H19, IGF-1R mRNA and GAPDH gene (control gene) will be determined by Real-Time Quantitative PCR
Study NCT02940002 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY1003803
Description: Simultaneous application of 10μl on psoriasis plaque and on healthy skin for 4 weeks and evaluation of pharmacodynamic effect
Study NCT02884635 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP1707
Description: Oral
Study NCT02884635 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral
Study NCT02884635 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Methotrexate will be orally administered at stable dose from at least 28 days prior to screening through the screening and treatment periods until the end of the follow-up period.
Study NCT02884635 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Methotrexate
Description: Methotrexate will be orally administered at stable dose from at least 28 days prior to screening through the screening and treatment periods until the end of the follow-up period.
Study NCT03754049 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TLC599
Description: TLC599 is manufactured with the proprietary lipid formulation in lyophilized form (BioSeizer) for the reconstitution with the aqueous DSP (active ingredient).
Study NCT03754049 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DSP
Description: Dexamethasone sodium phosphate (DSP) is a glucocorticoid widely used in the treatment of joint pain such as gout, osteoarthritis and rheumatoid arthritis via IA injection.
Study NCT02940002 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clobetasol propionate
Description: Simultaneous application of 10μl on psoriasis plaque and on healthy skin for 4 weeks and evaluation of pharmacodynamic effect
Study NCT02940002 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Betamethasone/calcipotriene
Description: Simultaneous application of 10μl on healthy skin for 4 weeks and evaluation of pharmacodynamic effect
Study NCT02556476 — intervention group
Intervention type: PROCEDURE
Intervention: mechanical ventilation
Description: ventilator support for the patients presenting with acute respiratory failure
Study NCT02556476 — intervention group
Intervention type: PROCEDURE
Intervention: neuromuscular blockade
Description: paralysis of the skeletal muscles in order to optimize mechanical ventilation, especially during ARDS
Study NCT02556476 — intervention group
Intervention type: PROCEDURE
Intervention: renal replacement therapy
Description: the procedures used to treat acute kidney injury
Study NCT02556476 — intervention group
Intervention type: PROCEDURE
Intervention: non-invasive ventilation
Description: Procedure used for ventilation support in patients with congestive heart failure, pulmonary edema, COPD and some other conditions.
Study NCT00432601 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: type of decision aid
Description: We will be comparing two decision aids (MCC vs. NCCN) in terms of their impact on decision making and patient-physician communication.
Study NCT00432601 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: type of decision aid
Description: We will be comparing two decision aids (MCC vs. NCCN) in terms of their impact on decision making and patient-physician communication.
Study NCT00829985 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Glycerinated German Cockroach Allergenic Extract
Description: Concentrated (1:20 w/v) daily doses of glycerinated German cockroach allergenic extract placed under the tongue to dissolve. The extract is also administered during the preliminary dosing visits in up to five escalating doses or until the maximum study dose (420 microliters, 1:20 w/v) is achieved.
Study NCT00829985 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Daily doses of cockroach allergenic extract placebo placed under the tongue to dissolve
Study NCT04426760 — intervention group
Intervention type: PROCEDURE
Intervention: Transcervical resection of fibroids
Description: Transcervical resection of fibroids
Study NCT04426760 — intervention group
Intervention type: PROCEDURE
Intervention: Myomectomy per laparoscopy or laparotomy
Description: Myomectomy per laparoscopy or laparotomy
Study NCT03575481 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: The RAT and The TST
Description: The RAT (ReoGo; Motorika Medical, Caesarea, Israel) The TST protocol included the conventional, repetitive, task-oriented training of the affected arm.
Study NCT03606070 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: PET-MRI
Description: * a PET-MRI examination performed before the chemoradiotherapy treatment (so-called baseline PET-MRI)~* a PET-MRI examination performed midway through treatment (PET-MRI1 under treatment), after receiving 33 ± 4 Gy (approximately 2.5 months after the first PET-MRI).
Study NCT02401295 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATRA
Study NCT02401295 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib
Study NCT02401295 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Study NCT02274038 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baseline 18F-thymidine (FLT) PET/CT
Description: FLT is a fluoro-labelled thymidine analog used as a radiotracer of tumor proliferation in PET/CT imaging. This baseline scan will be used to compare post-therapy FLT-PET/CT in order to assess change in tumor accumulation of FLT.
Study NCT02274038 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Post-therapy 18F-thymidine (FLT) PET/CT to assess for pemetrexed induced tumor FLT flare
Description: FLT is a fluoro-labelled thymidine analog used as a radiotracer of tumor proliferation in PET/CT imaging. This scan will be performed on the day of starting pemetrexed therapy (within 24hrs of starting pemetrexed) and used to compare to baseline FLT-PET/CT in order to assess change in tumor accumulation of FLT. The objective is to assess for early pemetrexed induced changes in tumor accumulation of FLT known as FLT flare.
Study NCT02274038 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Post-therapy 18F-thymidine (FLT) PET/CT to assess for pemetrexed induced changes in tumor proliferation
Description: FLT is a fluoro-labelled thymidine analog used as a radiotracer of tumor proliferation in PET/CT imaging. This scan will be performed 2-4 weeks after starting pemetrexed therapy and used to compare to baseline FLT-PET/CT in order to assess change in tumor accumulation of FLT. The objective is to assess for pemetrexed induced changes in tumor accumulation of FLT as a surrogate measure of tumor proliferation.
Study NCT01766700 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 2 no calorie beverages per day
Description: Weekly and monthly lifestyle weight loss/maintenance classes.
Study NCT01766700 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: 2 water beverages per day
Description: Weekly and monthly lifestyle weight loss/maintenance classes.
Study NCT04508387 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Group HH (heated-humidified)
Description: Group CD patients were administered dry CO2 via insufflator at room temperature (21°C), while Group HH patients were administered 95% humidified CO2 insufflation at 37°C. The study was planned as a randomized and double-blind study, where patients were not informed of their group. During the operation and in the postoperative period, the patients were followed up by two different anesthetists. All patients were given information and training on the anesthesia method, the use of the patient-controlled-analgesia device and the visual analog scale the day before the operation. The patients' demographic data (age, weight, height, etc.) and their basal systolic, diastolic and mean blood pressures and heart rates were measured prior to the operation and recorded on the case report form. Both groups received the standard general anesthesia protocol. Laparoscopic surgery was performed in the same manner for all cases by AA.